Publication: Characterization of human urinary metabolites of the antimalarial piperaquine
dc.contributor.author | J. Tarning | en_US |
dc.contributor.author | Y. Bergqvist | en_US |
dc.contributor.author | N. P. Day | en_US |
dc.contributor.author | J. Bergquist | en_US |
dc.contributor.author | B. Arvidsson | en_US |
dc.contributor.author | N. J. White | en_US |
dc.contributor.author | M. Ashton | en_US |
dc.contributor.author | N. Lindegårdh | en_US |
dc.contributor.other | Goteborg University, Sahlgrenska Academy | en_US |
dc.contributor.other | Hogskolan Dalarna | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Nuffield Department of Clinical Medicine | en_US |
dc.contributor.other | Uppsala Universitet | en_US |
dc.date.accessioned | 2018-08-20T07:23:41Z | |
dc.date.available | 2018-08-20T07:23:41Z | |
dc.date.issued | 2006-12-01 | en_US |
dc.description.abstract | Five metabolites of the antimalarial piperaquine (PQ) (1,3-bis-[4-(7- chloroquinolyl-4)-piperazinyl-1]-propane) have been identified and their molecular structures characterized. After a p.o. dose of dihydroartemisinin- piperaquine, urine collected over 16 h from two healthy subjects was analyzed using liquid chromatography (LC)/UV, LC/tandem mass spectrometry (MS/MS), Fourier transform ion cyclotron resonance (FTICR)/MS, and H NMR. Five different peaks were recognized as possible metabolites [M1, 320 m/z; M2, M3, and M4, 551 m/z (PQ + 16 m/z); and M5, 567 m/z (PQ + 32 m/z)] using LC/MS/MS with gradient elution. The proposed carboxylic M1 has a theoretical monoisotopic molecular mass of 320.1166 m/z, which is in accordance with the FTICR/MS (320.1168 m/z) findings. The LC/MS/MS results also showed a 551 m/z metabolite (M2) with a distinct difference both in polarity and fragmentation pattern compared with PQ, 7-hydroxypiperaquine, and the other 551 m/z metabolites. We suggest that this is caused by N-oxidation of PQ. The results showed two metabolites (M3 and M4) with a molecular ion at 551 m/z and similar fragmentation pattern as both PQ and 7-hydroxypiperaquine; therefore, they are likely to be hydroxylated PQ metabolites. The molecular structures of M1 and M2 were also confirmed using H NMR. Urinary excretion rate in one subject suggested a terminal elimination half-life of about 53 days for M1. Assuming formation rate-limiting kinetics, this would support recent findings that the terminal elimination half-life of PQ has been underestimated previously. Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics. | en_US |
dc.identifier.citation | Drug Metabolism and Disposition. Vol.34, No.12 (2006), 2011-2019 | en_US |
dc.identifier.doi | 10.1124/dmd.106.011494 | en_US |
dc.identifier.issn | 1521009X | en_US |
dc.identifier.issn | 00909556 | en_US |
dc.identifier.other | 2-s2.0-33751549060 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/23897 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33751549060&origin=inward | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | Characterization of human urinary metabolites of the antimalarial piperaquine | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33751549060&origin=inward | en_US |